PRIMARY SCLEROSING CHOLANGITIS

This Phase 3 study tests whether the drug elafibranor can slow liver damage in adults with primary sclerosing cholangitis (PSC), a rare disease that scars the bile ducts. About 350 participants will receive either elafibranor or a placebo daily for several years. The main goal is…

This early-stage trial is testing whether a transplant of healthy gut bacteria can be safely given to people with primary sclerosing cholangitis (PSC), a rare liver disease. Twenty-eight adults will first take antibiotics to clear their gut, then receive capsules containing freez…

This study tests whether transplanting healthy stool bacteria (FMT) can improve liver health in people with primary sclerosing cholangitis (PSC) and inflammatory bowel disease. 58 adults will receive either FMT or a placebo via colonoscopy and enemas. The main goal is to see if F…

This early-stage study tests whether the experimental drug TAK-781 is safe and tolerable in healthy volunteers and in people with primary sclerosing cholangitis (PSC), a chronic liver disease. The study also looks at how the body processes the drug. About 134 participants will be…

This early study tests whether siplizumab, given at the time of liver transplant, can safely prevent the immune system from attacking the new liver. Up to 8 adults with autoimmune hepatitis or primary sclerosing cholangitis will receive two doses. The main goal is to check for se…

This Phase 2 trial tests whether the drug BRS201 (a form of vitamin B12) can improve liver health in people with primary sclerosing cholangitis (PSC), a rare liver disease. Over 8 weeks, 28 participants will take either the drug or a placebo for 4 weeks each, in random order. The…

This study is gathering health information from 2,000 adults with primary sclerosing cholangitis (PSC) to build a real-world data comparator group. The goal is to help design and run future drug trials more efficiently by providing a control group from real patient experiences. P…

This study aims to understand what causes primary sclerosing cholangitis (PSC), a rare chronic liver disease. About 143 adults with PSC will provide blood, saliva, urine, stool, and tissue samples, plus undergo imaging and procedures like colonoscopy and liver biopsy. No treatmen…

This study follows 1,000 children with primary sclerosing cholangitis (PSC), a rare liver disease that damages bile ducts. Researchers will collect medical data, DNA, and symptom reports over time to understand how the disease progresses and affects daily life. The goal is to ide…

This study is using advanced whole-genome sequencing to find hidden genetic causes of cholestatic liver disease in adults whose condition remains unexplained after standard tests. Researchers will compare the DNA of 60 affected adults to a large group of healthy controls. The goa…

This study looks at the gut bacteria of 3000 adults with chronic liver diseases like autoimmune hepatitis and fatty liver. Researchers want to find specific bacteria linked to each disease to better understand how the gut and liver interact. This is an observational study, not a …

This early-phase study at Stanford University is testing whether the statin drug rosuvastatin changes bile acid levels and gut bacteria in people with primary sclerosing cholangitis (PSC), a liver disease with no cure. Researchers will enroll 15 adults with PSC and inflammatory b…

This study collects bile and bile duct cells from people with Primary Sclerosing Cholangitis (PSC) and healthy volunteers to grow mini-livers called organoids. The goal is to understand how PSC progresses and leads to liver cancer. No treatment is given; it is purely for research…

This study is creating a large collection of blood, urine, stool, bile, and bile duct cells from up to 9,150 people with cholestatic liver diseases like primary biliary cholangitis and primary sclerosing cholangitis, as well as from healthy volunteers. The samples and medical dat…

This study aims to identify specific blood markers that can distinguish hepatitis caused by immune checkpoint inhibitors from other types of autoimmune hepatitis. Researchers will collect blood samples and liver tissue from 60 adults receiving immunotherapy. The goal is to improv…